Stem cell secretome attenuates acute rejection in rat lung allotransplant.
Animals
Disease Models, Animal
Graft Rejection
/ pathology
Immunosuppression Therapy
/ methods
Immunosuppressive Agents
/ therapeutic use
Lung
/ pathology
Lung Transplantation
/ adverse effects
Male
Mesenchymal Stem Cell Transplantation
/ methods
Mesenchymal Stem Cells
/ cytology
Rats
Rats, Inbred BN
Rats, Inbred F344
Transplantation, Homologous
Acute rejection
Lung transplantation
Paracrine factors
Secretome
Stem cells
Journal
Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399
Informations de publication
Date de publication:
01 05 2019
01 05 2019
Historique:
received:
24
07
2018
revised:
06
09
2018
accepted:
23
09
2018
pubmed:
7
12
2018
medline:
14
1
2020
entrez:
4
12
2018
Statut:
ppublish
Résumé
Stem cells secrete significant amounts of bioactive factors in their secretome that can be immunosuppressive. We studied the effect of the secretome obtained from bone marrow-derived mesenchymal stem cells (BMSC-sec) in combination with cyclosporine A following acute rejection of lung allografts in the rat. Lung allotransplants were performed from male Brown Norway donor rats to recipient male Fisher 344 rats. Rat BMSC-sec was introduced intratracheally in the recipient every day after the transplant until the day the animal was sacrificed. Group A (n = 5) received control medium and cyclosporine A (2.5 mg/kg body weight intraperitoneally) for 5 days post-transplant and group B (n = 5) received BMSC-sec and cyclosporine A. Blood gas analysis was performed to assess graft function at day 5 only from the graft, and the tissue was sampled for measurement of the wet/dry ratio and histological grading of rejection. All control animals (group A) showed severe signs of rejection. At day 5 grafts in group B showed improved gas exchange (i.e. mean PaO2 mmHg 237.9 ± 130 mmHg vs 24.9 ± 7.8 mmHg in group A). Histological examination according to the International Society of Heart and Lung Transplantation (ISHLT) revealed moderate to severe rejection in all animals in group A (III B) and a significant improvement in group B (I-IIA). The wet/dry ratio was also reduced in group B to 6.19 ± 0.6 compared to 9.36 ± 2 in group A. Furthermore, in vitro T-cell proliferation was reduced after treatment with BMSC-sec for CD 3 cells (69.55 ± 07 vs 73 ± 0.84), for CD 4 (24.95 ± 1.2 vs 27.75 ± 0.21) and for CD 8 cells (3.75 ± 0.2 vs 5.68 ± 0.02). The BMSC-sec is a promising novel cell-based therapeutic option for acute rejection in a rat lung allograft model.
Identifiants
pubmed: 30508108
pii: 5224541
doi: 10.1093/icvts/ivy306
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-818Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.